The serotonin receptor subtype 5-HT 1A was one of the first serotonin receptor subtypes pharmacologically characterized. Over the last twenty years the 5-HT 1A receptor has been the object of intense research efforts as witnessed by the 5-HT 1A acting drugs marketed as anxiolytics. In recent years, several new chemical entities targeting the 5-HT 1A receptor (alone or in combination with other molecular targets) have been proposed for novel therapeutic indications (neuroprotection, cognitive impairment, Parkinson Disease and related disorders, pain treatment). The present review will focus on those 5-HT 1A receptor agents that entered preclinical trials starting from 2000.
INTRODUCTION
Serotonin (5-HT) exerts its diverse actions by binding to distinct cell surface receptors which have been classified into many groups on the basis of their pharmacological responses to specific ligands, sequence similarities at the gene and amino acid levels, gene organization, and second messenger coupling pathways. The development of ligands with enhanced specificity, the molecular cloning of several of these receptors, and subsequent heterologous expression have unambiguously confirmed the existence of at least 14 subtypes of serotonin receptors [1] . Most of the serotonin receptors, except the 5-HT 3 receptor, belong to the large family of seven transmembrane domain G-protein coupled receptors [2] . The 5-HT 1A receptor is an important member of this large family of receptors. The 5-HT 1A receptor has been the most extensively studied of the serotonin receptors for a number of reasons. One of the main reasons resides on the early availability of the selective agonist 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT) [3, 4] that has allowed extensive biochemical, physiological, and pharmacological characterization of the receptor. The 5-HT 1A receptor was the first among all the serotonin receptors to be cloned and sequenced [5] [6] [7] .
According to the data collected by the PubMed [8] starting from 1990, the number of publications per year containing the term "5-HT1A" into the title and the abstract revealed an interesting trend (Fig. 1) . The number of papers increased constantly until 1996, with a peak of about 400 papers. In 2000, the number of publications nearly halved, whereas in recent years the number of papers increased, witnessing a renewed interest.
In 1986, buspirone was introduced by Bristol-Myers Squibb under the brand name BuSpar as a medication to treat patients suffering from generalized anxiety disorder (GAD) . Clinical trials demonstrated that buspirone was effective in the treatment of anxiety with efficacy and dosage comparable to diazepam or chlorazepate. Moreover, due to its different site of action it lacked of the anticonvulsant, sedative, and muscle-relaxant properties associated with other anxiolytics. Also, it lacked liability to produce physical *Address correspondence to this author at the Università degli Studi di Bari, Dipartimento Farmaco-Chimico, via Orabona, 4, 70125, Bari, Italy; Tel: +39-080-5442798; Fax: +39-080-5442231; E-mail: leopoldo@farmchim.uniba.it dependence or to significantly interact with central nervous system depressants such as ethanol. With its low incidence of sedation, buspirone was presented as a useful addition to the treatments available for GAD and it was seen as a promising therapeutic agent in patients in whom daytime alertness was particularly important [9, 10] . Buspirone also appeared to have efficacy in major depressive disorders, suggesting that modulation of 5-HT 1A receptor function might have clinical antidepressant properties [11] . However, buspirone is poorly selective and this originates several unwanted side-effects including dizziness, nausea, insomnia, headaches, nervousness, and lightheadness. Moreover, the main metabolite of buspirone, 1-(2-pyrimidyl)piperazine, displays a variety of pharmacological actions.
The development of buspirone opened the avenue for the search of new anxiolytic drugs acting at 5-HT 1A receptors. In recent years a number of 5-HT 1A agonists entered Phase II clinical trials as anxiolytics (S 15535, alnespirone, MN-305, lesopitron, gepirone, flesinoxan; Fig. 2) . On the other hand, the possible involvement of 5-HT 1A receptor function in depression therapy originated several compounds acting at various molecular targets, including 5-HT 1A receptors. For instance, flibanserin, DU-125530, vilazodone, robalzotan, and OPC-14523 (Fig. 3) Besides these well-established therapeutical areas, other, yet interesting, therapeutical perspectives have emerged from the careful evaluation of the effects elicited by some 5-HT 1A receptors agents. The present review will focus on the therapeutic potential of 5-HT 1A agents that entered preclinical trials starting from 2000 and will highlight their key pharmacological features.
NEUROPROTECTION
One of the fundamental mechanisms in the process of ischemic cell death is ionic imbalance and excitotoxicity mediated by glutamate release. The neuroanatomical distribution of 5-HT 1A receptors, coupled with hyperpolarization of cell membrane and glutamate release inhibition elicited by 5-HT 1A receptor agonists, suggested a neuroprotective role on the brain in cerebral ischemic conditions. 5-HT 1A receptors are highly expressed postsynaptically in areas of the brain that are most sensitive to neuronal damage following ischemic stroke or brain trauma, such as hippocampus (CA1 and CA3 sectors and dentate gyrus), cerebral cortex and basal forebrain nuclei [12] [13] [14] . The 5-HT 1A receptors exert an inhibitory effect on the firing activity of neurons in these brain areas. Stimulation of the 5-HT 1A subtype has been shown to induce neuronal hyperpolarization, most likely mediated by activation of Gprotein coupled K + channels, and consequent inhibition of neuronal activity [13, [15] [16] [17] . In addition, 5-HT 1A receptor agonists produce voltage-independent blockade of N-, P-/Q-, and T-type voltage-dependent Ca 2+ channels via G-proteinmediated signaling mechanisms or via a membranedelimited pathway, respectively [18] . Furthermore, 5-HT 1A signaling inhibits L-type voltage-dependent Ca 2+ channel through a G-protein-mediated diffusible cytosolic messenger, 19 and by this way abrogate Ca 2+ entry into nerve cells [17] . 5-HT 1A receptor agonists can reduce glutamate release from nerve terminals [17, 20] , which is most likely mediated through activation of presynaptic 5-HT 1A receptors located on glutamatergic terminals [21, 22] .
The potential of 5-HT 1A receptor agonists for the treatment of ischemic brain disorders was revealed by several studies starting from 1990. In particular, 8-OH-DPAT, buspirone, gepirone, ipsapirone, Bay R 1531 were tested in rat and mouse after induction of focal cerebral ischemia and demonstrated to be efficacious in decreasing the area of cerebral damage [23] . Also urapidil and CM 57493 demonstrated to reduce dose dependently the infarct size in rodent models of focal and global ischemia [24] . On the other hand, conflicting results were obtained in gerbil models. Bode-Gruel and coworkers [25] found that the partial agonist ipsapirone and the full agonist Bay R 1531 displayed neuroprotectant activity, whereas gepirone and 8-OH-DPAT were ineffective. Piera et al. 26 studied 8-OH-DPAT, buspirone and flesinoxan on neuronal degeneration induced by transient global ischemia. 8-OH-DPAT confir- All the above studies clearly pointed out the potential of 5-HT 1A receptor agonists as neuroprotectants. However, the recovery from ischemic damage elicited by the above agonists was quite limited at doses not suitable for therapeutic use. For instance, after permanent middle cerebral artery occlusion (p-MCA-O), CM 57493 reduced the cortical infarct volume by 30% at 1-5 mg/kg dose and ipsapirone produced a 60% reduction at 30 mg/kg.
Starting from these observations, it was emphasized that, besides selectivity over other receptor systems, the level of affinity and intrinsic activity played a pivotal role in antischemic effect. It was hypothesized that the therapeutic spectrum of a 5-HT 1A receptor agonist could be optimized by increasing the apparent intrinsic activity at pre-and post synaptic 5-HT 1A receptor population. With this respect, De Vry observed that the so-called full agonist 8-OH-DPAT appeared not to have the same intrinsic activity as 5-HT itself at those receptors responsible for the membrane hyperpolarizing effects of 5-HT in the CA1 sector of hippocampus [13] . These findings and considerations stimulated the search for more selective 5-HT 1A receptor ligands endowed with full agonist properties, demonstrated in a wide array of functional assays.
Repinotan (formerly known as BAY x 3407; Fig. 5 ) represents a potent and relatively selective 5-HT 1A agonist which fulfills the above mentioned requirements. The pharmacological profile of this agent as well as its neuroprotective properties in several models of ischemia and brain trauma have been extensively reviewed [27] [28] [29] . Here is reported a brief summary of repinotan pharmacological profile.
Repinotan binds with high affinity at 5-HT 1A receptors from various tissues, including calf hippocampus (K i = 0.19 nM), rat cortex (K i = 0.24 nM), rat hippocampus (K i = 0.58 nM), human cortex (K i = 0.25 nM), and recombinant 5-HT 1A receptors (K i = 0.4 nM). Repinotan binds also with relatively high to moderate affinity to the other monoaminergic receptors: 1 and 2 adrenergic (K i = 6 and 7 nM, respectively); 5-HT 7 and 5-HT 1D (K i = 7 and 36 nM, respectively); dopamine D 2 and D 4 (48 and 91 nM, respectively). In more than 50 other receptor binding assays, weak affinity was only detected for 5-HT 2C receptors (K i = 310 nM) and binding sites (K i = 176 nM). The binding profile of repinotan is considered to be relatively selective because at least one order of magnitude differentiates its binding to the 5-HT 1A receptor from its binding to other receptors.
The intrinsic activity of repinotan has been assessed by using several models. In the forskolin-stimulated adenylate cyclase assay in rat hippocampal tissue, a model of (Fig. 6) . The agonistic properties of repinotan were confirmed also at presynaptic level in an in vitro electrophysiological assay. In fact, in rat brain slice preparation containing dorsal raphe nucleus (DRN), repinotan induced a long lasting inhibition of neuronal firing at concentration of 1 nM. Also in vivo, repinotan has been characterized as a 5-HT 1A receptor agonist. Repinotan suppressed 5-HT neuronal firing in the DRN after intravenous application in anesthetized rat. In another in vivo model, rats trained to discriminate 8-OH-DPAT from vehicle, potent and complete generalization was obtained after administration of repinotan.
The agonistic properties at pre-and postsynaptic 5-HT 1A receptors of repinotan were also evidenced in vivo. In fact, repinotan induced potent and dose-dependent effects in behavioral models highly sensitive to 5-HT 1A receptor agonism (rat forced swimming test, shock-induced ultrasonic vocalization). Finally, repinotan induced, at higher doses, different components of the 5-HT-dependent behavioural syndrome in rats, including reciprocal forepaw threading, Straub tail, increase in locomotor activity, hindlimb abduction and flat body posture, and hypothermia. Repinotan has been tested in various models that mimic different aspects of human brain injury: permanent focal cerebral ischemia model involving pMCA-O; reperfusion injury model by transient middle artery occlusion (tMCA-O); traumatic brain injury (TBI) model involving induction of acute subdural hematoma (aSDH). Also, two different administration techniques have been used: i.e. continuous infusion and trible bolus injection ( Table 1) . Repinotan demonstrated pronounced neuroprotectant properties. Moreover, repinotan showed a therapeutic time-window of at least 5 h from the ischemic event in the same animal models ( Table 2) .
In 2004 Bayer HealthCare [30] reported the ending of development program for repinotan (Branosyn), because it did not fulfill expectations after completion of Phase IIb clinical trial. However, no scientific report about this point appeared into the literature.
The japanese company Daiichi Asubio Pharma has disclosed in recent years the selective 5-HT 1A receptor agonist piclozotan (SUN N4057, Fig. 5 ). This compound showed remarkable neuroprotective activity in a tMCA-O model. In an early report, piclozotan was reported as structurally derived from the prototypical "long-chain" arylpiperazine derivative buspirone [31] . Piclozotan demonstrated improved selectivity over dopamine D 2 receptor as compared to buspirone (piclozotan: 5-HT 1A IC 50 forskolin-stimulated adenylate cyclase activity in plasma membrane prepared from the rat hippocampus (IC 50 = 2.67 nM). On the basis of such profile, the authors investigated in vivo the neuroprotective effect of piclozotan in a rat model of transient focal ischemia. The compound was subcutaneously administered immediately after t-MCA-O in rats. The neuronal damage was quantitated from the level of peripheral type benzodiazepine binding sites (PTBBS) in ipsilateral cortical and striatal homogenates, 10 days after recirculation. Piclozotan and buspirone (1 mg/kg s.c.) reduced the increase in PTBBS levels of 63% and 53%, respectively. The hypothermic effect of piclozotan was not found to be related to the neuroprotective effect [32] . Piclozotan is currently in Phase IIb clinical trials for treatment of ischemic stroke [33] . Unfortunately, no other data on intrinsic activity at 5-HT 1A receptor of piclozotan both in vitro and in vivo are available. Therefore a peer-topeer comparison of repinotan and piclozotan cannot be done and a general profile for 5-HT 1A agonists with anti ischemic properties cannot be drawn.
COGNITIVE IMPAIRMENT
Alzheimer's disease is a neurodegenerative disorder characterized by multiple deficits in neurotrasmitters function. Numerous studies have documented a reduction in glutamate release in several brain areas (neocortex, hippocampus, enthorinal cortex). Glutamate plays a pivotal role in cognition, learning and memory processes. In particular, the activation of glutamatergic neurotrasmission facilitates memory, whereas transmission blockade impairs learning and memory. On the other hand, the serotonergic system results to be hyperactive as a result of the enhanced turnover of serotonin which would reduce the neuronal firing through stimulation of 5-HT 1A receptors.
It has been demonstrated that 5-HT 1A receptors located on presynaptic glutamatergic neurons could inhibit both excitatory neurotrasmission and release of glutamate in vitro. Therefore, it has been suggested that 5-HT 1A receptor antagonists could have a facilitatory effect on glutamatergic transmission by blocking the hyperpolarization and changes in Ca 2+ flux induced by inhibitory serotonergic tone [34] . Finally, it has been speculated that 5-HT 1A receptor antagonists may decrease the formation of -amyloid peptide which has been clearly linked to neuronal plaques that are the pathological hallmarks of the disease [35] .
Starting from 1993, several selective 5-HT 1A receptor antagonists has been developed, including WAY-100135, a Data taken from Ref. [29] . [36] . Although WAY-100635 has been extensively used in determining the consequences of 5-HT 1A receptor blockade, it is not orally active and has a relatively short half-life that has precluded its clinical development [37] . Nonetheless, WAY-100635 has served in multiple preclinical studies to support the hypothesis that 5-HT 1A receptor antagonists improve performance in cognitive tasks. For example, WAY-100635: a) attenuates the impairment of spatial learning caused by the intrahippocampal administration of scopolamine, 7-chlorokynurenic acid, or MK-801, in rats [34] ; b) reverses the choice accuracy deficit in nucleus basalis magnocellularislesioned rats, but does not shorten correct response latencies [38] ; c) reverses 8-OH-DPAT induced deficits in a rat recognition memory task [39] ; d) shows pro-cognitive effects in water maze and passive avoidance in rats [40] and passive avoidance in mice [41] .
The selective 5-HT 1A receptor antagonists lecozotan (Fig.  6) is currently under investigation in advanced phase II clinical trials because it demonstrated in vivo its positive role in relevant models for cognition [42, 43] . In a microdialysis assay using conscious rats, 8-OH-DPAT induced a decrease in extracellular levels of 5-HT in the hippocampus. Pretreatment with lecozotan completely attenuated the response to 8-OH-DPAT. Treatment with lecozotan alone did not produce any agonistic effects, confirming the lack of intrinsic activity even at high doses. The lack of agonistic activity in this assay, indicated that lecozotan acted as a full presynaptic antagonist. In another assay, pretreatment with lecozotan significantly antagonized the inhibition of DRN neuronal firing produced by 8-OH-DPAT. Again, lecozotan alone did not produce changes in DRN firing, indicating antagonistic activity also at postsynaptic 5-HT 1A receptors. Moreover, pharmacological studies using fixed ratio responding in rats and squirrel monkeys demonstrated that lecozotan was a potent and competitive antagonist in vivo. Lecozotan also demonstrated oral activity in this model, producing a parallel rightward shift in the 8-OH-DPAT dose/response curve.
Lecozotan demonstrated cognition enhancing effect in a number of animal models of learning and memory. Treatment with lecozotan prior testing completely reversed the cognitive deficits induced by the uncompetitive NMDA antagonist MK-801 in both visual and visuospatial discrimination tasks in marmosets. Lecozotan alone had no effect. The effect of lecozotan on cognitive performance has been also examined in aged rhesus monkeys using a delayed match-to-sample task. Treatment with lecozotan resulted in a significant improvement in task accuracy above baseline (16.5%).
Currently, lecozotan is in Phase II clinical trials for Alzheimer Disease's [44] . Very recently, the potent and selective 5-HT 1A receptor silent antagonist WAY-101405 (Fig. 6 ) endowed with similar cognition enhancer properties as lecozotan has been reported [45] .
PARKINSON'S DISEASE AND RELATED DISORDERS
As already mentioned above, some atypical antipsychotics shared the common feature of agonistic activity at 5-HT 1A receptor. These compounds were characterized by low incidence of motor side-effects caused by activation of dopamine D 2 receptors. On such basis, it was hypothesized that 5-HT 1A activation alone or in combination with activity at D 2 -like receptors could be relevant for drugs to treat abnormal involuntary movements (dyskinesia) in Parkinson's disease (PD) or for antiparkinsonian agents with reduced side-effects, respectively.
It is well recognized that serotoninergic system dysfunction and reduced serotonin concentrations occur in the basal ganglia of patients with PD [46] . In animal models of PD, striatal dopaminergic mechanisms can be influenced by drugs interacting with serotoninergic neurons, including 5-HT 1A receptor agonists [47] . In patients with advanced PD, striatal serotoninergic terminals serve as an important site for the decarboxylation of exogenous levodopa to dopamine (DA) [48] . Consequently, 5-HT 1A receptor agonists act at striatal serotoninergic terminals to modify the level of DA produced by levodopa treatment. In addition, clinical and preclinical observations suggest that an increase in serotoninergic transmission can contribute to the appearance of dyskinesias [49] [50] [51] . These considerations have suggested that stimulation of striatal 5-HT 1A autoreceptors might benefit extrapyramidal dysfunction and, in particular, ameliorate the motor complications associated with levodopa therapy.
In recent years, sarizotan and SLV 308 (Fig. 5) , two compounds endowed with agonistic activity at 5-HT 1A receptor and activity at dopamine D 2 -like receptors (D 2-4 ), entered preclinical trials. In particular, sarizotan has been proposed as antidiskynetic agent, whereas SLV 308 as antiparkinsonian drug with limited motor side-effects.
Sarizotan showed affinities in the nanomolar range for the 5-HT 1A receptors (rat IC 50 = 6.5 nM; human IC 50 = 0.1 nM), D 2 (rat IC 50 = 15.1 nM; human IC 50 = 17 nM), hD 3 (IC 50 = 6.8 nM) and hD 4.2 (IC 50 = 2.4 nM) receptors. The affinity of sarizotan for dopamine D 1 receptors as well as for the other 5-HT receptor subtypes was at least two orders of magnitude lower (except human 5-HT 7 receptor: IC 50 = 10 nM). Affinities to about 50 other receptors, ion channels and transporters were found to be at least >1000 nM.
The intrinsic activity of sarizotan has been assessed in comparison with 8-OH-DPAT in two different assays. Sarizotan and 8-OH-DPAT prevented in a concentration dependent way forskolin-stimulated elevation of the intracellular cAMP level. In particular, sarizotan showed EC 50 = 1.5 nM; E max = 100% at 1 μM. It is noteworthy that sarizotan displayed efficacy (E max ) comparable to that of 8-OH-DPAT, and about six-to tenfold higher potency. In the guinea pig ileum preparation, sarizotan and 8-OH-DPAT concentration-dependently inhibited the electrically-induced contractions with IC 50 values of 150 nM (E max = 40% at 1 μM) and 580 nM (E max = 46% at 10 μM), respectively.
Sarizotan displays partial DA agonist profile in vivo. In intact rats, sarizotan increased striatal DOPA accumulation, an indicator of DA receptor blocking properties. In reserpinized rats, sarizotan decrease DOPA accumulation in the striatum. Although the effect is modest as compared with that of dopamine full agonists, this decrease indicates that sarizotan have some level of intrinsic dopaminergic activity [52] .
The ability of sarizotan to affect the response alterations complicating levodopa treatment of PD has been assessed in animal models of parkinsonism by Bibbiani et al. [53] In 6-OH-DA-lesioned rats, sarizotan had no effect on the acute rotational response to levodopa but did attenuate the shortening in motor response duration induced by chronic levodopa treatment. In MPTP-lesioned monkeys, sarizotan alone had no effect on parkinsonian severity or on the antiparkinsonian response to levodopa. In contrast, sarizotan elicited a considerable reduction of levodopa-induced choreiform dyskinesias. In both species, the motoric effects of sarizotan were blocked by WAY-100635, indicating that the observed responses were most likely mediated by stimulation of 5-HT 1A autoreceptor. Moreover, the authors argued that the antidyskinetic action of sarizotan was unlikely to reflect D 2 -like receptor blockade because a functionally significant effect at these sites was incompatible with the absence of any reduction in the antiparkinsonian action of levodopa as well as the ability of WAY-100635 to block motoric responses to sarizotan. Furthermore, sarizotan was found unable to reduce the antiparkinsonian and dyskinesiogenic effects of the D 2 agonist quinpirole alone, thus it did not exerted inhibitory effects at D 2 or D 3 receptors.
However, Kuzhikandathil & Bartoszyk [54] pointed out that the above behavioral effects of sarizotan were not directly determined by using D 2 -like dopamine receptorspecific antagonists. Therefore, the authors characterized in detail the functional profile of sarizotan on D 2S , D 2L , D 3 , D 4.2 and D 4.4 dopamine receptors, individually expressed in AtT-20 neuroendocrine cell line. This cell line is an ideal heterologous expression system for studying D 2 -like dopamine receptors since it natively expresses many of the effector molecules that couple to the different D 2 -like receptors and also exhibits neuronal properties. In particular, the authors evaluated the effect of sarizotan on two different signaling pathways: a) the D 2 -like receptor-mediated inhibition of adenylyl cyclase and b) the D 2 -like receptormediated activation of G-protein coupled inward rectifier K + channels (GIRK). It was determined that, depending on the receptor subtype and signaling pathway, sarizotan was both a partial agonist and a full agonist ( Table 3 ). In particular, using the coupling of In 2005, a press release announced that Solvay Pharmaceuticals advanced in Phase III clinical trials the mixed D 2 /D 3 /5-HT 1A agent SLV308. This compound, which combines high potency partial agonism at dopamine D 2 and D 3 receptors with full efficacy low potency 5-HT 1A receptor agonism, has been studied in in vivo models of PD. Dopaminergic therapies, including levodopa and dopamine agonists, are the pillars of PD therapy. However, they are associated with a high probability of motor complications (dyskinesias and motor fluctuations), psychotic-like symptoms such as hallucinations (probably due to the overstimulation of extra-striatal dopamine receptors), orthostatic hypotension, somnolence, and other side-effects [58, 59] .
SVL308 has been developed on the basis of a multitarget strategy to obtain antiparkinsonian drugs devoted of motor side-effects. It was hypothesized that partial dopamine D 2 and D 3 receptor agonists should not induce motor sideeffects because partial agonists would hypothetically be capable of stimulating D 2 and D 3 receptors when the dopaminergic tone is low, while being able to counteract excessive stimulation of the D 2 and D 3 receptors when the dopaminergic tone is high [60] . Moreover, the 5-HT 1A receptor agonist component could ameliorate the induction of dyskinesia [61, 62] . In vitro experiments demonstrated that SLV308 possessed partial agonist effect at dopamine D 2 and D 3 receptors. Intrinsic activity of SLV308 at hD 2L receptors has been assessed using the ability of the D 2L receptor to attenuate forskolin-stimulated cAMP accumulation. SLV308 showed partial efficacy up to 50% at D 2L receptors as compared to quinpirole (pEC 50 SLV308 showed efficacy in animal models of PD, lowering spontaneous activity when tested on locomotor behaviour in open field tests. Also, SLV308 stimulated turning behavior in rats with unilateral 6-OH-DA lesions of the substantia nigra pars compacta and submaximally (vs. quinpirole) decreased dialysate dopamine levels in the rat nucleus accumbens. In MPTP-treated marmosets SLV308 produced marked and long-lasting antiparkinsonian effects. Finally, 5-HT 1A receptor agonism in vitro did translate into 5-HT 1A mediated behavior in vivo (forced swim test, stress induced ultrasonic pup vocalization) [63, 64] .
No clinical data on SLV308, nor any insight on the relative contribution of the D 2 , D 3 , and 5-HT 1A components in mechanism of action of SLV308 are available to date. SLV308 (pardoprunox) is currently being studied in five clinical studies for treatment of early stage PD [65] .
PAIN TREATMENT
In a paper published in 1990, Millan & Colpaert reported that 5-HT 1A partial agonists attenuated morphine-evoked antinociception, revealing an interaction between opioid and 5-HT 1A receptors in the control of nociception [66] . Starting from this observation, Colpaert and coworkers [67, 68] developed the new concept that in nociceptive systems any input causes two effects that are opposite in sign. Opioid receptor activation produces both analgesia as a so-called first-order effect and hyperalgesia as a second-order effect. Upon chronic exposure to opioid, the second-order hyperalgesia grows and neutralizes the first-order effect, thus offering a description of the neuroadaptive tolerance and sensitization that develops with opioids. According to this concept, 5-HT 1A receptor activation produces dual, bidirectional effects that should amount to the mirror opposite of those produced by opioids. Therefore, stimulation of peripheral nociceptors would initially produce pain as a first-order effect, but also hypoalgesia as a second-order effect; with cronicity, this second order hypoalgesia counteract the first order pain and remarkably develop into increasingly powerful analgesia.
The identification of F-13640 (Fig. 5) , a highly selective and high efficacy 5-HT 1A agonist enabled to prove this concept, evidencing that pro-and antinociceptive actions of 5-HT 1A ligands depend on their efficacy at 5-HT 1A receptor [69] .
In 1999, Vacher and coworkers at Pierre Fabre SA reported on the design, synthesis, and preliminary pharmacological characterization of a series of 6-substitutedpyridin-2-ylmethylamine derivatives [70] . Particular attention was given to metabolic stability of the new series of 5-HT 1A agonists, to ensure the identification of potent 5-HT 1A agonists suitable for in vivo studies. Among the reported compounds, F-13640 displayed the most relevant pharmacological profile. In radioligand binding experiments, F-13640 displaced [ 3 H]8-OH-DPAT from rat and human 5-HT 1A receptors (pK i = 9.07 and 9.49, respectively). The hyper-and hypoalgesic effects of F-13640 were studied in normal rats and in the formalin model of tonic nociceptive pain, respectively [69] . F-13640 produced both hyperalgesia and analgesia, in a direct function of the extent of 5-HT 1A receptors activation. With this respect, the authors emphasized the importance of the very-high-efficacy 5-HT 1A receptor activation elicited by F-13640.
F-13640 revealed to exert an analgesic action in rat models of acute, tonic and chronic nociceptive pain that was rivaled only by large doses of high-efficacy μ-opioid receptor agonists [71] . In models of neuropathic allodynia of peripheral or central origin, chronic F-13640 administration caused an analgesia that surpasses that observed with morphine, ketamine, imipramine and gabapentin. F-13640 was shown to produce long-lasting, preemptive and curativelike actions in neuropathic allodynia. The Annual Report 2005 by Pierre Fabre referred that F-13640 was being studied in Phase II clinical trials [72] . No clinical data in humans for this compound are available to date.
CONCLUDING REMARKS
The serotonin 5-HT 1A receptor is likely the most studied subtype among the serotonergic receptors. Over the years, the intense research by medicinal chemists has allowed the identification of various classes of 5-HT 1A receptor ligands. The use of some prototypical 5-HT 1A agonists and antagonists has led to meaningful insight into the pathophysiological role of 5-HT 1A receptor. It became soon apparent that 5-HT 1A receptor was involved in anxiety and depression and also that activation of this receptor would have beneficial effect on some unwanted side-effects of antipsychotic drugs. In recent years, the identification of some potent and selective 5-HT 1A receptor agents led to the definition of newer therapeutic areas wherein the 5-HT 1A receptors were involved. Among the selective agonists, repinotan and piclozotan demonstrated anti-ischemic properties, whereas F-13640 showed remarkable analgesic properties. The 5-HT 1A agonist component of sarizotan and SLV308 has been indicated to have beneficial effect on levodopa-induced dyskinesia. On the other hand, the antagonist lecozotan has demonstrated cognition enhancing effects. A key aspect emerging from the studies on repinotan and F-13640 is the in-depth characterization of agonist intrinsic activity. In fact, many 5-HT 1A agonists have been characterized only in comparison with 8-OH-DPAT which show, at least in some biological systems, partial agonist properties as compared to the native agonist 5-HT. Therefore, the evaluation in different in vitro and in vivo models of 5-HT 1A receptor activation will give an accurate characterization of agonistic properties.
In recent years, early ADMET studies have been employed in order to significantly reduce the failure rate in the development of drug candidates. This concept has been also applied in serotonin 5-HT 1A receptor field, leading to lecozotan, the first orally active silent antagonist. Similarly, Epix Pharmaceuticals rapidly progresses in Phase 2b clinical trials for major depressive disorders the potent and selective agonist PRX-00023 [73] .
Although some of the discussed agents will not reach the market as new drugs, they are already revealing as powerful tools for elucidation of molecular mechanisms in which the 5-HT 1A receptor is involved. Therefore, it will not be surprising if other newer therapeutic indications will be hypothesized in the near future based on the studies performed on agents that today have failed to reach the market. This has already begun as witnessed by a number of patents claiming 5-HT 1A agonists useful for treatment of sexual disorders. 
